Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19026681 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS OF N-SULFONAMIDE AND USE THEREOF | January 2025 | February 2026 | Allow | 13 | 1 | 1 | Yes | No |
| 18268001 | QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | June 2023 | June 2025 | Allow | 24 | 0 | 0 | No | No |
| 18336828 | MACROCYCLIC MUSK LACTONES AND USES THEREOF | June 2023 | August 2025 | Abandon | 26 | 1 | 1 | No | No |
| 18257371 | 14-CHLORO-BETA-ELEMENE NITRIC OXIDE DONOR DERIVATIVE AND PREPARATION METHOD AND USE THEREOF | June 2023 | March 2026 | Allow | 33 | 1 | 0 | Yes | No |
| 18044049 | CD73 INHIBITOR AND APPLICATION THEREOF IN MEDICINE | March 2023 | March 2026 | Abandon | 36 | 0 | 1 | No | No |
| 18009725 | PHARMACEUTICAL COMPOSITION FOR SARS-COV-2 PREVENTION AND/OR TREATMENT | December 2022 | February 2026 | Abandon | 38 | 1 | 0 | No | No |
| 18008859 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | December 2022 | February 2026 | Abandon | 38 | 0 | 1 | No | No |
| 18062892 | AMINO-PYRIMIDINE CYCLO-AMIDES | December 2022 | January 2026 | Allow | 38 | 0 | 1 | Yes | No |
| 17916947 | MEAYAMYCIN AND ITS ANALOGUES, METHODS FOR THEIR PREPARATION, AND METHODS OF USE | October 2022 | December 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17907117 | SALT AND CRYSTALLINE FORMS OF FGFR4 INHIBITOR AND USES THEREOF | September 2022 | December 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17912498 | INHALATIONAL THERAPY FOR COVID-19 | September 2022 | March 2026 | Abandon | 42 | 0 | 1 | No | No |
| 17906017 | PHARMACEUTICAL COMBINATION COMPRISING PYRIDINO[1,2-A]PYRIMIDINONE COMPOUND | September 2022 | November 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17905536 | METHODS TO TREAT CANCER USING (R)-N-(3-FLUORO-4-((3-((1-HYDROXYPROPAN-2-YL)AMINO)-1H-PYRAZOLO[3,4-B]PYRIDIN-4-YL)OXY)PHENYL)-3-(4-FLUOROPHENYL)-1-ISOPROPYL-2,4-DIOXO-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXAMIDE | September 2022 | February 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17904997 | NOVEL SELECTIVE MAO-B INHIBITOR DRG-MAOB-2 FOR USE IN TREATMENT OF NEURODEGENERATIVE DISEASES | August 2022 | July 2025 | Allow | 35 | 1 | 0 | Yes | No |
| 17904570 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | August 2022 | March 2026 | Allow | 43 | 1 | 1 | Yes | No |
| 17799234 | QUINOLYL PHOSPHINE OXIDE COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | August 2022 | November 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17795280 | NEW RYLENE DICARBOXIMIDES | July 2022 | January 2026 | Allow | 42 | 0 | 1 | Yes | No |
| 17794641 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS AURORA A SELECTIVE INHIBITORS | July 2022 | November 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17792878 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | July 2022 | August 2025 | Allow | 37 | 0 | 1 | Yes | No |
| 17810052 | HETEROCYCLIC SULFOXIMINE COMPOUND AND INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | June 2022 | February 2026 | Abandon | 43 | 1 | 1 | No | No |
| 17773197 | ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS | April 2022 | December 2025 | Allow | 44 | 1 | 1 | No | No |
| 17754902 | ESTROGEN-RELATED RECEPTOR ALPHA MODULATORS | April 2022 | September 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17709556 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | March 2022 | December 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17638448 | CONTROLLED RELEASE TOFACITINIB COMPOSITIONS | February 2022 | September 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17634172 | Methods for Increasing the Bioavailability of OTC and Pharmaceutical Drugs | February 2022 | July 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17595711 | HETEROCYCLIC IMMUNOMODULATORS AS PDL1 CHECKPOINT INHIBITOR | November 2021 | January 2026 | Allow | 50 | 2 | 1 | No | No |
| 17435703 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | October 2021 | September 2025 | Allow | 49 | 1 | 1 | Yes | No |
| 17442754 | PHARMACEUTICAL SALTS OF BENZOTHIAZOL COMPOUNDS, POLYMORPHS AND METHODS FOR PREPARATION THEREOF | September 2021 | February 2025 | Allow | 41 | 0 | 1 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner JOHNSON, CHRISTOPHER LINDSAY works in Art Unit 1691 and has examined 3 patent applications in our dataset. With an allowance rate of 100.0%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 49 months.
Examiner JOHNSON, CHRISTOPHER LINDSAY's allowance rate of 100.0% places them in the 94% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by JOHNSON, CHRISTOPHER LINDSAY receive 1.00 office actions before reaching final disposition. This places the examiner in the 8% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by JOHNSON, CHRISTOPHER LINDSAY is 49 months. This places the examiner in the 6% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +0.0% benefit to allowance rate for applications examined by JOHNSON, CHRISTOPHER LINDSAY. This interview benefit is in the 12% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
This examiner enters after-final amendments leading to allowance in 100.0% of cases where such amendments are filed. This entry rate is in the 98% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 4% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.